Jane Street’s ChemoCentryx, Inc. CCXI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-7,822
Closed -$404K 10851
2022
Q3
$404K Sell
7,822
-65,074
-89% -$2.69M ﹤0.01% 7079
2022
Q2
$1.81M Sell
72,896
-41,935
-37% -$924K ﹤0.01% 4357
2022
Q1
$2.88M Buy
114,831
+26,385
+30% +$741K ﹤0.01% 4036
2021
Q4
$3.22M Buy
88,446
+34,529
+64% +$1.21M ﹤0.01% 3573
2021
Q3
$921K Sell
53,917
-260,862
-83% -$4.06M ﹤0.01% 6076
2021
Q2
$4.21M Buy
314,779
+298,996
+1,894% +$7.37M ﹤0.01% 2951
2021
Q1
$809K Sell
15,783
-31,353
-67% -$1.89M ﹤0.01% 5868
2020
Q4
$2.92M Sell
47,136
-20,927
-31% -$1.2M ﹤0.01% 2854
2020
Q3
$3.73M Buy
68,063
+44,899
+194% +$2.42M ﹤0.01% 2193
2020
Q2
$1.33M Buy
23,164
+14,037
+154% +$764K ﹤0.01% 3654
2020
Q1
$367K Buy
+9,127
New +$388K ﹤0.01% 3990
2018
Q2
Sell
-14,429
Closed -$196K 5811
2018
Q1
$196K Buy
+14,429
New +$149K ﹤0.01% 4464
2016
Q3
Sell
-16,035
Closed -$72K 4691
2016
Q2
$72K Buy
+16,035
New +$60.2K ﹤0.01% 3931
2014
Q2
Sell
-53,968
Closed -$358K 3267
2014
Q1
$358K Sell
53,968
-34,190
-39% -$238K ﹤0.01% 1840
2013
Q4
$510K Buy
+88,158
New +$455K 0.01% 1217

Other funds holding CCXI

Jane Street's CCXI Position: Q4 2022 in Review

Jane Street sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 7,822 shares — an estimated $404K sold.

Jane Street first reported a position in CCXI in Q4 2013 and held it in 15 quarters. The position peaked at $4.21M in Q2 2021. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.

  • Jane Street reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
  • Jane Street sold 7,822 ChemoCentryx, Inc. shares in Q4 2022, an estimated $404K.
  • Jane Street first reported a position in ChemoCentryx, Inc. in Q4 2013 and held it in 15 quarters.
  • Jane Street's ChemoCentryx, Inc. position peaked at $4.21M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.

Based on Jane Street's 13F filing for Q4 2022, filed 15 Feb 2023.